Clinical Characteristics of the Patients
| Patient No. . | Sex/ Age-150 . | Lymphocyte Count/μL . | Stage-151 . | Treatment Received-152 . | Time Since Last Treatment . | DNA-PK Activity-153 . |
|---|---|---|---|---|---|---|
| Untreated patients | ||||||
| U1 | F/51 | 80,700 | B | 6.9 | ||
| U2 | F/59 | 28,800 | B | 5.3 | ||
| U3 | F/84 | 83,100 | B | 9.8 | ||
| U4 | F/64 | 76,200 | B | 3.4 | ||
| U5 | F/65 | 31,000 | C | 2.2 | ||
| U6 | M/81 | 49,900 | A | 2.2 | ||
| U7 | M/59 | 48,300 | A | 1.7 | ||
| U8 | M/85 | 58,500 | B | 1.9 | ||
| U9 | M/50 | 40,200 | A | 22.8 | ||
| U10 | M/92 | 53,500 | A | 14.9 | ||
| U11 | F/71 | 29,800 | A | 44.5 | ||
| U12 | M/66 | 136,400 | B | 0.9 | ||
| U13 | F/69 | 49,900 | A | 3.4 | ||
| U14 | M/74 | 35,600 | A | 2.9 | ||
| U15 | F/52 | 42,000 | B | 5.8 | ||
| U16 | F/52 | 110,400 | B | 1.2 | ||
| Treated patients with resistance to NMs | ||||||
| T1 | M/53 | 57,500 | C | CLB, CYC, CHOP | 12 mo | 19.0 |
| T2 | F/78 | 233,500 | C | Fluda | On treatment | 13.0 |
| T3 | F/59 | 74,800 | C | CLB, CYC, Fluda | 6 mo | 13.4 |
| T4 | F/87 | 77,800 | C | CLB | On treatment | 16.9 |
| T5 | F/82 | 32,700 | C | CLB, CYC | On treatment | 12.7 |
| T6 | F/72 | 128,100 | C | CLB | On treatment | 32.5 |
| T7 | F/56 | 102,100 | B | CLB, CYC | On treatment | 28.3 |
| T8 | F/60 | 158,500 | C | CLB, CYC | On treatment | 26.3 |
| T9 | M/63 | 104,700 | C | CLB, CYC | 3 mo | 16.2 |
| T10 | M/86 | 58,100 | B | CLB | On treatment | 28.8 |
| T11 | F/76 | 127,300 | C | CLB | On treatment | 55.8 |
| T12 | F/70 | 61,900 | B | CLB | 12 mo | 35.6 |
| T13 | M/54 | 127,300 | C | CLB | 1 mo | 32.3 |
| T14 | M/76 | 167,800 | B | CLB, CVP, Fluda | 12 mo | 20.7 |
| T15 | M/69 | 398,500 | C | CLB, CVP, Fluda | 3 mo | 19.4 |
| T16 | M/77 | 88,400 | B | CLB | 5 mo | 25.6 |
| T17 | M/66 | 31,300 | B | CLB, CYC, Fluda | On treatment | 34.9 |
| T18 | M/52 | 56,700 | B | CLB, CHOP CLB | On treatment | 14.9 |
| Patient No. . | Sex/ Age-150 . | Lymphocyte Count/μL . | Stage-151 . | Treatment Received-152 . | Time Since Last Treatment . | DNA-PK Activity-153 . |
|---|---|---|---|---|---|---|
| Untreated patients | ||||||
| U1 | F/51 | 80,700 | B | 6.9 | ||
| U2 | F/59 | 28,800 | B | 5.3 | ||
| U3 | F/84 | 83,100 | B | 9.8 | ||
| U4 | F/64 | 76,200 | B | 3.4 | ||
| U5 | F/65 | 31,000 | C | 2.2 | ||
| U6 | M/81 | 49,900 | A | 2.2 | ||
| U7 | M/59 | 48,300 | A | 1.7 | ||
| U8 | M/85 | 58,500 | B | 1.9 | ||
| U9 | M/50 | 40,200 | A | 22.8 | ||
| U10 | M/92 | 53,500 | A | 14.9 | ||
| U11 | F/71 | 29,800 | A | 44.5 | ||
| U12 | M/66 | 136,400 | B | 0.9 | ||
| U13 | F/69 | 49,900 | A | 3.4 | ||
| U14 | M/74 | 35,600 | A | 2.9 | ||
| U15 | F/52 | 42,000 | B | 5.8 | ||
| U16 | F/52 | 110,400 | B | 1.2 | ||
| Treated patients with resistance to NMs | ||||||
| T1 | M/53 | 57,500 | C | CLB, CYC, CHOP | 12 mo | 19.0 |
| T2 | F/78 | 233,500 | C | Fluda | On treatment | 13.0 |
| T3 | F/59 | 74,800 | C | CLB, CYC, Fluda | 6 mo | 13.4 |
| T4 | F/87 | 77,800 | C | CLB | On treatment | 16.9 |
| T5 | F/82 | 32,700 | C | CLB, CYC | On treatment | 12.7 |
| T6 | F/72 | 128,100 | C | CLB | On treatment | 32.5 |
| T7 | F/56 | 102,100 | B | CLB, CYC | On treatment | 28.3 |
| T8 | F/60 | 158,500 | C | CLB, CYC | On treatment | 26.3 |
| T9 | M/63 | 104,700 | C | CLB, CYC | 3 mo | 16.2 |
| T10 | M/86 | 58,100 | B | CLB | On treatment | 28.8 |
| T11 | F/76 | 127,300 | C | CLB | On treatment | 55.8 |
| T12 | F/70 | 61,900 | B | CLB | 12 mo | 35.6 |
| T13 | M/54 | 127,300 | C | CLB | 1 mo | 32.3 |
| T14 | M/76 | 167,800 | B | CLB, CVP, Fluda | 12 mo | 20.7 |
| T15 | M/69 | 398,500 | C | CLB, CVP, Fluda | 3 mo | 19.4 |
| T16 | M/77 | 88,400 | B | CLB | 5 mo | 25.6 |
| T17 | M/66 | 31,300 | B | CLB, CYC, Fluda | On treatment | 34.9 |
| T18 | M/52 | 56,700 | B | CLB, CHOP CLB | On treatment | 14.9 |
Response to therapy to date for the untreated patients is as follows: U1, U2, U3, U6, U7, U8, U10, U11, U13, and U16 have not received any treatment. U4 was treated for 8+ months and had an excellent response to CLB (normalization of lymphocyte count, lymphadenopathy: pretreatment node size of 3 to 4 cm vposttreatment node size of ≤0.5 cm). U5 and U12 were treated for 8+ and 36 months, respectively, and had a complete response to CLB (normalization of lymphocyte count, disappearance of lymphadenopathy, and no other evidence of disease). U9 had no response to chlorambucil as previously defined24 (lymphocyte count >35,000 and no decrease in lymphadenopathy after 6 months of chlorambucil treatment). U14 was treated with CLB for 3 months. He had an excellent response as evidenced by a normalization of his lymphocyte count, disappearance of lymphadenopathy and splenomegaly, but his platelet count did not return to normal (95,000/μL). U15 did not tolerate CLB treatment because of nausea and vomiting. She took 30% to 40% of the first two courses (CLB 20 mg and 12 mg every day ×5 every 4 weeks). She took only 1 day of the third course of CLB 4 mg daily. Despite this she showed a partial response as evidenced by a decrease in the size of a large cervical lymph node mass (9 × 9 cm to <3 × 3 cm).
Sex: M, male; F, female; age in years.
Staging is according to Binet et al.22
CYC, cyclosphosphamide; Fluda, fludarabine.
DNA-PK activity is expressed in arbitrary units. For each sample, the results represent the mean of at least two experiments with variability of <15%.